Cryno Biotech is developing a novel GLP-1 receptor agonist with promising preliminary study results in prevention and treatment of 2 type diabetes mellitus, as well as its complications such as diabetic neuropathy, muscular dystrophy, and endotheliopathy. Our polypeptide is optimized to penetrate peripheral and central nervous systems.
Development phase: Pre-clinical studies
Indication: Peripheral neuropathy, Type 2 Diabetes and its complications.
Target: GLP-1 receptor
Preliminary results: CRY-001 is a molecule based on modified Exendin-4. Our structure was proved to increase CRY-001 half-life as well as to improve blood-brain barrier permeability and cell membrane permeability. In vivo studies have shown promising results in removing pain in neuropathic pain models and slowing down B cells apoptotic rate in diabetes models. Analgesic effect and regeneration of nerve fibers were observed in alcohol-induced neuropathy models. Central effects of CRY-001, such that restored myelin expression levels in brain tissues were registered.
Market: $4B GLP-1 receptor agonist market with anticipated 12.4% CAGR over next 10 years. Peripheral neuropathies affect 3-4% of people over the age of 55.
The team of the project has experience in bringing tens of drugs to markets worldwide. We combine both the flexibility of a fast moving startup company and seasoned strategical decisions of team members with Big Pharma top management experience.
27.03.2017 Cryno has successfully passed Skolkovo expertise
Our team has successfully passed the expertise of Skolkovo Innovation Center. We are finalizing the documentation to become Skolkovo Innovation Center residents. It will provide us access to infrastructure and funds required to conduct all the necessary preclinical and clinical trials to get CRY-001 to the market.
25.12.2016 Meet us at JP Morgan Healthcare Conference (8-12 January 2017, San Francisco)
You can meet two of Cryno team members in San Francisco during the JP Morgan Healthcare Conference. Please contact us via firstname.lastname@example.org to request a meeting.